Pembrolizumab is a Programmed Death 1 (PD-1) inhibitor used to treat advanced malignant melanoma and metastatic non-small cell lung cancer. It causes various endocrinological side effects including immune mediated thyroiditis. Thyroiditis caused by Pembrolizumab can mimic other immune mediated thyroiditis like Hashimoto thyroiditis and Grave’s disease.
Journal of Internal Medicine and Patient Care
Tachamo, N., Lohani, S., Nazir, S., Joshi, R., & Deshmukh, M. (2017). Pembrolizumab-Associated Hypothyroidism: Case Report and Review of Literature. Journal of Internal Medicine and Patient Care, 1 (1), 107-107. Retrieved from https://scholarcommons.towerhealth.org/gme_int_med_resident_program_read/140